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Abstract
Background: Cholera is a major cause of mortality and morbidity in underdeveloped countries including Nepal.
Recently drug resistance in Vibrio cholerae has become a serious problem mainly in developing countries. The main
objectives of our study were to investigate the occurrence of Vibrio cholerae in stool samples from patients with
watery diarrhea and to determine the antimicrobial susceptibility patterns of V. cholerae isolates.
Methods: A total of 116 stool samples from patients suffering from watery diarrhea during July to December 2012
were obtained from outbreak areas from all over Nepal. Alkaline peptone water and thiosulphate citrate bile salt
sucrose agar (TCBS) were used to isolate the Vibrio cholerae. The isolates were identified with the help of colony
morphology, Gram’s staining, conventional biochemical testing, serotyping and biotyping. Antimicrobial susceptibility
testing was performed by determining the minimum inhibitory concentration (MIC) by agar dilution method.
Results: Vibrio cholerae was isolated from 26.72 % of total samples. All isolated Vibrio cholerae were confirmed to
be Vibrio cholerae serogoup O1 biotype El Tor and serotype Ogawa. All isolates were resistant to ampicillin and
cotrimoxazole. Twenty nine isolates were resistant toward two different classes of antibiotics, one strain was
resistant to three different classes of antibiotics and one strain was resistant to four different classes of antibiotics.
According to the definition of the multidrug resistant bacteria; 6.45 % of the strains of Vibrio cholerae were found
to be multidrug resistant.
Conclusions: Cholera due to multidrug resistant Vibrio cholerae is also possible in Nepal. According to the
antimicrobial susceptibility pattern of Vibrio cholerae in our study we recommend to use any antibiotics among
tetracycline, doxycycline, levofloxacin, azithromycin, chloramphenicol and ciprofloxacin for preliminary treatment of
cholera in Nepal.
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Background
Vibrio cholerae is one of the most notorious enteric
pathogens responsible for many cholera outbreaks [1].
Once commonly detected throughout the world, the in-
fection is now mainly confined to the under-developed
countries, where the conditions of drinking water, sanita-
tion and hygiene are not well maintained. It is endemic in
Africa, South Asia, and Latin America. Cholera outbreaks
usually occur when the drinking water and public sani-
tation systems are disrupted by natural disasters like
earthquakes, tsunamis, volcanic eruptions, landslides and
floods or due to crowding like in war displaced refugee
camps [2]. Globally, there are an estimated 3–5 millions
cholera cases and 100,000–120,000 deaths every year.
Commonly, lack of prompt, proper treatment leads to
shock within 6–12 h followed by death occurring between
18 h and several days [3].
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Cholera is endemic in Nepal [4] and causes massive
morbidity and mortality in every monsoon in both urban
and rural areas. In Nepal every year 30,000–40,000
people die due to diarrheal diseases, majority of the
deaths occurring due to cholera [5]. In recent years,
large cholera outbreaks have occurred in western regions
of Nepal. In Jajarkot in 2009, within a three weeks
period of a cholera outbreak 3,000 people were affected
and more than 80 died. The outbreak was associated
with poor hygiene and use of contaminated water. The
lack of proper medical facilities has further increased the
morbidity and mortality in such places [4]. In Nepalgunj,
an outbreak of cholera affected more than 1500 people
with eight deaths in late July and August 2010 [6]. Out-
breaks from other parts of Nepal have also been re-
ported [7–10]. Although several pathogens may be
responsible for causing acute diarrhea in humans, it is
important to investigate Vibrio cholerae as the causative
agent, particularly in resource poor settings because it
can be fatal, causing death within several hours and it is
highly contagious with a propensity to cause epidemics
or pandemics [9].
Recently, drug resistance in Vibrio cholerae has be-
come a serious problem mainly in developing countries
and reports of drug resistance to different antibiotics
(including ampicillin, tetracycline, streptomycin, kana-
mycin, trimethoprim, sulphonamides and gentamicin)
have appeared from many cholera-endemic countries
[11]. Further cholera cases due to multidrug resistant
Vibrio cholerae have been reported from all around the
globe [12]. Multidrug resistant (MDR) bacteria are the
bacteria showing resistance towards three or more than
three different classes of antibiotics [13].
In Nepal, only a few studies have been done targeting
the identification of drug resistance in Vibrio cholerae
and limited information is available about the MDR
cholera. In this study we investigated the occurrence of
V. cholerae in stool samples from patients with watery
diarrhea and determined the antimicrobial susceptibility
patterns of V. cholerae isolates. This study will be
helpful for the clinicians to start the timely preliminary
treatment, by choosing the effective antibiotics for the
treatment of the cholera.
Methods
To determine the involvement of V. cholerae in causing
watery diarrhea and to determine their antimicrobial
susceptibility patterns, a community based study was
conducted during rainy season of 2012. For this a total
of 116 stool samples {Kathmandu (n = 65), Doti (n = 30),
Bajhang (n = 15), Saptari (n = 6)} from all patients suffer-
ing from watery diarrhea during July to December 2012
were received at National public health laboratory,
Kathmandu from outbreak areas from all over Nepal.
The samples were transported within 24 h of collection
using alkaline peptone water. The stool samples inocu-
lated in enrichment media (alkaline peptone water) were
incubated at 37 °C for overnight and were subcultured
on selective media, TCBS. The characteristic yellow
colored (sucrose fermenting) colonies grown on TCBS,
after 24 h of aerobic incubation at 37 °C were subjected
to biochemical testing [14] and serotyping using specific
antisera (Denka Seiken, Tokyo, Japan) following manu-
factures instructions. The biotyping was performed with
the help of Voges Proskauer test (by using methyl red
Voges Proskauer media), chicken erythrocyte agglutin-
ation test and susceptibility to polymixin B (50 iu). The
El Tor biotype is Voges Proskauer test positive, shows
agglutination and is resistant to polymixin B [14].
Antimicrobial susceptibility testing to ampicillin, cotri-
moxazole, tetracycline, doxycycline, chloramphenicol,
ciprofloxacin, levofloxacin and azithromycin was per-
formed by determining the minimum inhibitory con-
centration (MIC) by agar dilution method as suggested
by Andrews [15]. The different dilutions used for
ampicillin, tetracycline, doxycycline, chloramphenicol,
ciprofloxacin, levofloxacin and azithromycin were
0.5 μg/ml, 1 μg/ml, 2 μg/ml, 4 μg/ml, 8 μg/ml, 16 μg/
ml, 32 μg/ml, 64 μg/ml, 128 μg/ml, 256 μg/ml. For
cotrimoxazole the different dilution used were 0.5/
9.5 μg/ml, 1/19 μg/ml, 2/38 μg/ml, 4/76 μg/ml, 8/
152 μg/ml, 16/204 μg/ml, 32/408 μg/ml. For the inter-
pretation of the antimicrobial susceptibility, MIC
breakpoints as suggested by CLSI document M45
guidelines were used [16].
Strains showing resistance towards ≥3 different classes
of drugs were considered as multidrug resistant [13].
The data obtained were entered into MS excel and ana-
lyzed using SPSS version 11.0. Chi square test was used
and p-value < 0.05 was taken as significant.
Results
Of total 116 samples received, 31 (26.72 %) samples
were found to be positive for V. cholerae among
which 13 (41.93 %) were from male patients and 18
(58.07 %) were from female patients. The cholera
agent was identified as Vibrio cholerae serogroup O1
biotype El Tor and serotype Ogawa. Most of V. cho-
lerae (70.97 %) were isolated from patients from
Kathmandu valley.
Age wise distribution of cholera cases
All age groups were found to be affected by cholera,
among which the people belonging to age group of
20–39 years were affected most and the people be-
longing to age group of above 60 years were affected
least (P < 0.05) (Table 1).
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Location wise distribution of cholera cases
33.84 % of the samples from Kathmandu and 20 % of
the samples from Bajhang were found to be positive for
V. cholerae (Table 2).
Antibiotic susceptibility patterns of Vibrio cholerae toward
different commonly used antibiotics
All 31 isolates were resistant to ampicillin and cotrimox-
azole. Similarly, all of the 31 isolates were sensitive to
tetracycline, doxycycline, levofloxacin and azithromycin,
while 30/31 (96.77 %) of the isolates were sensitive to
chloramphenicol and 29/31 (93.55 %) of the isolates
were sensitive to ciprofloxacin (Table 3).
Distribution of resistant strains of Vibrio cholerae against
different drugs
Twenty-nine isolates were resistant toward two different
classes of antibiotics, 1 strain was resistant to three dif-
ferent classes of antibiotics and one strain was resistant
to four different classes of antibiotics.
Drug resistant phenotype of V. cholerae isolates
The resistance of the strains to particular combination
of antibiotics was used to differenciate different drug
resistant phenotypes of V. cholerae. Twenty-nine of the
isolates were resistant to ampicillin (Amp)-cotrimoxazole
(TS), 1 isolate was resistant to ampicillin (Amp)-cotrimox-
azole (TS)-ciprofloxacin (CIP), 1 isolate was resistant to
ampicillin (Amp)-cotrimoxazole (TS)-ciprofloxacin (CIP)-
chloramphenicol (C) (Table 4).
Discussion
In the present study, the incidence of cholera among the
cases of watery diarrhea was found to be 26.72 % which
is similar to the findings of Tamang et al. (31 %) [7] and
Karki et al. (27.1 %) [17]. All the strains isolated in our
study were Vibrio cholerae serogroup O1 serotype Ogawa
and biotype El Tor and the finding is consistent with the
studies done in other parts of Nepal [2, 8, 10, 17]. How-
ever in contrast to our study, there was a total serotype
conversion to Inaba in 2005 and 2006 while in 2007, all
three serotypes {Ogawa (64 %), Inaba (35 %) and Hikojima
(1 %)} were isolated [18]. Such a serotype shifting is a
common phenomenon in V. cholerae [19–21].
The contaminated drinking water may have contrib-
uted for highest cholera cases in Kathmandu valley in
our study [22]. The drinking water of Kathmandu is
highly contaminated and is responsible for many other
water related infections also.
In our study 41.93 % of the Vibrio cholerae isolates
were isolated from male patients and 58.07 % of the
strains were isolated from female patients. Similar
results were also reported by Pun et al. who isolated
57 % of the strains from females and 43 % from males
[9]. We found the most affected age group to be 20–
39 years which is in accordance with the results reported
by other researchers [8, 9, 17, 23]. The food habits of
eating outside the home and consumption of street
foods may have contributed to the high incidence of
cholera in this age group.
Recently there have been reports of increased drug re-
sistance toward commonly used antibiotics among the
strains of Vibrio cholerae, causing serious problem in
management of the cholera cases [11]. In a study by
Karki et al. one hundred percent resistance was observed
for cotrimoxazole which supports our findings [17] but
in contrast to our study the isolates were found to be
highly susceptible to ampicillin [17] and high rates of
susceptibility were reported toward tetracycline, cipro-
floxacin, and erythromycin [17]. However, in our study
all isolates were sensitive to tetracycline, doxycycline,
levofloxacin and azithromycin, while most of the isolates
were sensitive to chloramphenicol (96.77 %) and cipro-
floxacin (93.55 %). As in our study all strains were
resistant to cotrimoxazole and ampicillin in the studies
done by Shrestha et al. [24] and Das et al. [25]. The
majority of V. cholerae strains were identified as sus-
ceptible to tetracycline (100 %), ciprofloxacin (90.9 %),
cefotaxime (81.8 %) and chloramphenicol (90.9 %) by
Shrestha et al. [24] and which is in accordance with the
results we have reported. However, in contrast to our
study, Shah et al. [26] showed that 81.8 % of strains
were resistant to tetracycline. Bhandari et al. reported
all isolates to be sensitive to commonly used antibiotics
except nalidixic acid and cotrimoxazole [8]. Similar as
in our study, 100 % resistance to ampicillin and 97.8 %
susceptibility to ciprofloxacin were reported by Karki
and Tiwari [27]. Generally, fluoroquinolones are highly
effective for treatment of cholera but recently
Table 1 Age wise distribution of cholera cases






Table 2 Location wise distribution of cholera cases
Location Total samples Positive samples (%)
Kathmandu 65 22 (33.85 %)
Doti 30 5 (16.67 %)
Bajhang 15 3 (20 %)
Saptari 6 1 (16.67 %)
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fluoroquinolone resistant strains of V. cholerae have
been reported from India [24]. The difference in drug
susceptibility of the strains of Vibrio cholerae isolated
from different places during different periods of time
may be due to mutation over time or due to the hap-
hazard uses of different antibiotics in different places or
during different periods of time [24]. And the antibi-
otics for the treatment of the cholera should be selected
on the basis of the local antimicrobial susceptibility
patterns of the Vibrio cholerae.
In our study we found 6.45 % of the strains to be
multidrug resistant but Shrestha et al. reported the rate
of multidrug resistance to be 100 % [24]. Multidrug
resistant Vibrio cholerae have been reported from all
around the world including Pakistan, Bangladesh, India
and Nepal [24]. Changing antibiogram profile of Vibrio
cholerae, developing MDR strains over years may be attrib-
uted to the spontaneous mutation due to indiscriminate
use of antibiotics or horizontal transfer of resistance genes
[24, 28]. So the use of the antibiotics for the management
of the cholera cases should be based on the antibiotic
susceptibility patterns of Vibrio cholerae in the particu-
lar area. Further, the rate of cholera can be controlled
to significant level by giving awareness regarding the
methods of control of the cholera (like personal hy-
giene) to the public. As shown in a recent review of
the USA Centers for Disease Control and Prevention
(CDC) surveillance data over a period of 21 years
(1990–2010), patients may get different antibiotics for
treatment [29]. But to investigate the potential correl-
ation between laboratory results and the surveillance
findings, antimicrobial susceptibility patterns to a
combination of antimicrobials were not available [29].
So the antimicrobial susceptibility patterns of the
Vibrio spp. to different commonly used antibiotics may
be helpful.
Limitation of the study
The main limitation of this study was lack of funding
and unavailability of sophisticated laboratory tests (as
this research was conducted in low income country), due
to which we could not use molecular methods to confirm
our results.
Conclusions
The cholera due to multidrug resistant Vibrio cholerae is
also possible in Nepal. The local antimicrobial suscepti-
bility patterns of the Vibrio cholerae is necessary to start
a proper timely treatment of cholera. The antimicrobial
therapy must be based on the antimicrobial susceptibility
testing report of Vibrio cholerae. According to the anti-
microbial susceptibility patterns of Vibrio cholerae in
our study we recommend to use any antibiotics among
tetracycline, doxycycline, levofloxacin, azithromycin,
chloramphenicol and ciprofloxacin for preliminary treat-
ment of cholera in Nepal.
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Table 3 Antibiotic susceptibility patterns of Vibrio cholerae toward different commonly used antibiotics
Antimicrobials No. of strains Susceptibility patterns
Sensitive (%) MIC (μg/ml) MIC breakpoints for
sensitive strains (μg/ml)
Resistant (%) MIC (μg/ml) MIC breakpoints for
resistant strains (μg/ml)
Ampicillin 31 0 - ≤8 100 64 ≥32
Cotrimoxazole 31 0 - ≤2/38 100 8/152 ≥4/76
Tetracycline 31 100 2 ≤4 0 - ≥16
Doxycycline 31 100 2 ≤4 0 - ≥16
Chloramphenicol 31 96.77 8 ≤8 3.23 32 ≥32
Ciprofloxacin 31 93.55 0.5 ≤1 6.45 4 ≥4
Levofloxacin 31 100 0.5 ≤2 0 - ≥8
Azithromycin 31 100 1 ≤2 0 - ≥8
Table 4 Drug resistant phenotype of V. cholerae isolates
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